Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Current Opinion in Immunology
|
February 21, 2012
The role of STAT5 in lymphocyte development and transformation
Lynn M Heltemes-Harris, Michael A Farrar
Nature Immunology
|
November 18, 2011
Turning transcription on or off with STAT5: when more is less
Michael A Farrar, Lynn M Heltemes Harris
Methods in Molecular Biology (Clifton, N.J.)
|
January 9, 2013
Constitutively active STAT5 constructs
Lynn M Heltemes-Harris, Michael A Farrar
Molecular Immunology
|
November 7, 2007
Activation-induced deaminase-mediated class switch recombination is blocked by anti-IgM signaling in a phosphatidylinositol 3-kinase-dependent fashion
Lynn M Heltemes-Harris, Patricia J Gearhart, Paritosh Ghosh, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 28, 2013
Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control
Michael Y Gerner, Lynn M Heltemes-Harris, Brian T Fife, et al.
Annals of the New York Academy of Sciences
|
February 1, 2011
The role of STAT5 in the development, function, and transformation of B and T lymphocytes
Lynn M Heltemes-Harris, Mark J L Willette, Kieng B Vang, et al.
Nature Communications
|
November 26, 2021
Single-cell analysis identifies dynamic gene expression networks that govern B cell development and transformation
Robin D Lee, Sarah A Munro, Todd P Knutson, et al.
Blood
|
March 11, 2022
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia
Sean I Tracy, Hrishi Venkatesh, Can Hekim, et al.
Nature Immunology
|
November 1, 2022
Nuclear corepressors NCOR1/NCOR2 regulate B cell development, maintain genomic integrity and prevent transformation
Robin D Lee, Todd P Knutson, Sarah A Munro, et al.
Biorxiv : the Preprint Server for Biology
|
July 9, 2025
PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSE
Elizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centenos, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Current Opinion in Immunology
|
February 21, 2012
The role of STAT5 in lymphocyte development and transformation
Lynn M Heltemes-Harris, Michael A Farrar
Nature Immunology
|
November 18, 2011
Turning transcription on or off with STAT5: when more is less
Michael A Farrar, Lynn M Heltemes Harris
Methods in Molecular Biology (Clifton, N.J.)
|
January 9, 2013
Constitutively active STAT5 constructs
Lynn M Heltemes-Harris, Michael A Farrar
Molecular Immunology
|
November 7, 2007
Activation-induced deaminase-mediated class switch recombination is blocked by anti-IgM signaling in a phosphatidylinositol 3-kinase-dependent fashion
Lynn M Heltemes-Harris, Patricia J Gearhart, Paritosh Ghosh, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 28, 2013
Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control
Michael Y Gerner, Lynn M Heltemes-Harris, Brian T Fife, et al.
Annals of the New York Academy of Sciences
|
February 1, 2011
The role of STAT5 in the development, function, and transformation of B and T lymphocytes
Lynn M Heltemes-Harris, Mark J L Willette, Kieng B Vang, et al.
Nature Communications
|
November 26, 2021
Single-cell analysis identifies dynamic gene expression networks that govern B cell development and transformation
Robin D Lee, Sarah A Munro, Todd P Knutson, et al.
Blood
|
March 11, 2022
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia
Sean I Tracy, Hrishi Venkatesh, Can Hekim, et al.
Nature Immunology
|
November 1, 2022
Nuclear corepressors NCOR1/NCOR2 regulate B cell development, maintain genomic integrity and prevent transformation
Robin D Lee, Todd P Knutson, Sarah A Munro, et al.
Biorxiv : the Preprint Server for Biology
|
July 9, 2025
PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSE
Elizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centenos, et al.
Page
of 2